← Back to Home

A brake on breast cancer cell growth lies in DNA: Study identifies a key link in androgen receptor–mediated cancer suppression

Deleting a DNA regulatory region called HRRINT3 weakened the androgen receptor’s ability to suppress breast cancer cell proliferation. This cell study adds a mechanistic clue behind a proposed treatment strategy, but predicting patient responses remains some way off.

By SURL BioNews

Hormonal signals can play different roles in breast cancer cells. Estrogen can drive the growth of estrogen receptor–positive (ER+) breast cancer, while the androgen receptor may help restrain proliferation. Developing the latter into a treatment strategy hinges on a key question: once the receptor is activated, what actually makes the cells slow down?

Research announced by the University of Adelaide on November 6 points to a DNA enhancer called HRRINT3. Such sequences help regulate gene activity; in the study models, the androgen receptor binds to HRRINT3 after being activated by androgens. Conducted by Maliha Wajahat and colleagues and published in *npj Breast Cancer*, the research involved collaboration among the University of Adelaide, the South Australian Health and Medical Research Institute (SAHMRI), and the University of Bordeaux in France.

The finding emerged from an unexpected turn. The team initially focused on ZBTB16 because higher expression of this gene in patients with ER+ breast cancer was associated with better survival. However, increasing or decreasing ZBTB16 expression in cell experiments did not change the androgen receptor’s ability to suppress growth. The research therefore shifted to HRRINT3, located within this gene: a gene associated with patient prognosis is not necessarily the component that directly carries out cancer suppression.

After the researchers used CRISPR to delete a small stretch of HRRINT3, the androgen receptor’s suppressive effect on breast cancer cell growth weakened. In the university’s announcement, co-author Zeyad Nassar noted that the deletion also disrupted broader androgen receptor signaling and increased the activity of genes that promote cell division. This extends HRRINT3’s role beyond simply regulating ZBTB16, suggesting that it may participate in a regulatory network that limits proliferation.

The team also observed faster proliferation after deleting this sequence in other androgen receptor–positive breast and prostate cancer cell models. However, these findings remain limited to the cells tested. They do not establish that different types of cancer all depend on the same suppressive mechanism, much less allow direct conclusions about how patients will respond to treatment.

Treatments that activate the androgen receptor are currently being studied for advanced ER+ breast cancer. HRRINT3’s value lies in helping clarify which molecular conditions this strategy requires to work. But the research materials published by Newswise explicitly classify this study as cell experiments; it has not yet demonstrated that HRRINT3 can serve as a predictor of treatment response in patients, nor has it established a treatment that directly manipulates this stretch of DNA. Moving from identifying a growth brake within cells to determining how to use it clinically still requires separate validation.

References

  1. Adelaide University
  2. Medical Xpress
  3. Newswise